Protara Stock: Orphan Drug Indications Drive A Heavily Undervalued Pipeline (NASDAQ:TARA)
· seekingalpha.com
Protara Therapeutics (TARA) buy thesis: $9.96 fair value vs ~$4, upside from TARA-002 & IV choline chloride, cash runway to 2028. Read here for more.
Protara Therapeutics, Inc. ( TARA ) is a pre-revenue company that does not have multiple assets in its pipeline but rather utilizes a "pipeline-in-a-product" ap...